IN3

INVESTIGATING THE SUPPLY AND DEMAND OF BUTANTAN DENGUE VACCINE IN BRAZIL

Garcia CR, Wilson-Barthes M, Coelho GE, Domingues C, Constena DO
1Johns Hopkins University, Baltimore, MD, USA, 2Ministerio de Salud, Brasilia, Brazil
OBJECTIVES: To evaluate the effect of dengue vaccine introduction and the economic impact of Butantan’s one-dose tetravalent dengue vaccine in Brazil. METHODS: We modeled the supply and demand of dengue vaccine nationally and for 6 key states using an existing strategic demand forecasting model. Input parameters on disease burden, vaccine product and pricing, production capacity, introduction strategies, and implementation costs were derived from local Brazilian stakeholders. Country-specific epidemiological data were obtained from disease reporting systems. Algorithms were developed to model 30-year dengue vaccine demand, total implementation cost, and vaccine impact using different age group introduction scenarios. Brazil’s highest dengue burden is among adults 19-46, and strategies targeting adults were modeled with the traditional child population. RESULTS: Initial strategies targeting all ages or ≥15 years old exceeded capacity and were considered not feasible. The demand for all strategies was below capacity for all scenarios, but by year 2048, the demand including boosters exceeds capacity for adult scenarios except for ages 19-31 (86.7%) and 31-46 (117.0%). At 85 per dose, the average annual total cost of introduction ranged from $21,059-$322,211 in the first years and $52,584-844,131 in the last ten years. The most affordable scenario is children 1-2 years, but this scenario had little impact on the disease burden (94% reduction in last 10 years). The combination scenario (staggered vaccine introduction for 2-46 years old for 5 years followed by 1-2 years) has the greatest impact with 90% and 79% reduction in cases and deaths respectively, and 84% annual treatment cost saving compared to the no vacination scenario. Vaccinating adults followed by children yields the greatest vaccine impact. Vaccine price, introduction strategy, age, and production capacity are major drivers of the demand and require consideration when deciding vaccine introduction. Discussion: Butantan has the potential to meet vaccine cases and associated costs substantially based on various introduction scenarios.

IN4

ECONOMIC COSTS OF BACTERIAL MENINGITIS: A SYSTEMATIC REVIEW

1Instituto Nacional de Salud Pública, México, D.F., 2Coordinación Centro de Investigación y Docencia, Hospital Infantil Néstor Arancibia, Bogotá, Colombia, 3Universidad del Sinú, Cartagena, Colombia, 4Unimedina. Grupo de Investigación en Economía de la Salud, Bogotá, Colombia
OBJECTIVES: A systematic review was used to assess economic costs of bacterial meningitis. METHODS: PubMed, Scopus and NHS-EED were searched to identify eligible papers. Economic evaluations that cost bacterial meningitis cases were selected. Economic cost and indirect costs were converted to 2012 international dollars and reported in ranges (minimum and maximum). RESULTS: We identified 621 non-duplicated articles. 118 papers were selected for full-text revision. 25 studies accomplished the inclusion criteria and were carried out in 27 countries. Most studies were undertaken in high-income countries (n=17). Only two studies took place in low income countries. Minimum and maximum laboratory mean costs were found in Burkina Faso ($6) and Chile ($1,604), respectively. Regarding to medical treatment, the mean minimal cost was $2,948 (98.4%) and the maximal $1,284 (Russia). Chile recorded the higher hospital cost of stay ($9,144) and Burkina Faso the lower ($1,107). Out-of-pocket health expenditures were estimated only in one study. (Sweden, $2,774). Among high income countries studies, the highest and lower total costs were reported in the United States and Suiza ($151,449 - $33,804). CONCLUSIONS: A large cost variability was found in the included studies. High-income countries economic costs were superior versus low-income countries costs. Even though Sub-Saharan countries has a high bacterial meningitis incidence only three studies were undertaken in this area.

MEDICAL DEVICE & DIAGNOSTIC RESEARCH STUDIES

MD1

EVALUACIÓN ECONÓMICA DEL CARDIO-DESFIBRILADOR IMPLANTABLE COMPARADO CON LA TERAPIA FARMACOLÓGICA ÓPTIMA PARA EL TRATAMIENTO DE LOS PACIENTES CON FALLA CARDIACA EN COLOMBIA

Alostortiz SC, Castro Pi, Cealomas M, Senior J, Salazar-Braga C, Giradella S, Ortíz S
1Universidad de Antioquia, Medellín, Colombia, 2Instituto de Evaluación Tecnológica en Salud (IETS), Bogotá, Colombia
OBJECTIVES: to determine, from the perspective of the system of health, the relationship between effectiveness of use of a CDI in comparison with no having it, to prevent the death of patients with cardiopathies ischemic or no ischemic, FL menor al 35%, DSV and extent NYHA II-II. METHODS: we developed a model of Markov that included costs, effectiveness, quality of life and supervision for a horizon of base of 10 years. The probabilities of transition were extrazoned of studies identified in the literature. The valorization of the resources used was realized in the national perspective of Colombia. RESULTS: the CDI has a probability of 0.80 to reduce the risk of death, a quality of life average (EQ-5D) of 0.82, with a cost of $30,345.73 per AV. In an analysis of subgroups, for the patients ischemics the RICE is $33,412.184 per AV, in the non ischemics is $47,030.266 per AV, and for patients with resulting cost of a polustomo of a study electronic. CONCLUSIONS: the cost-effective treatment of DCM (DBS) is a viable treatment option for patients with DCM and LVEF < 35%.

MD2

MEDICAL DEVICES – FROM LICENSING TO COVERAGE: HIGHLIGHTS FROM ARGENTINA, BRAZIL, COLOMBIA, AND MEXICO

Pepe C, Fahham L, Follador W, Valencia J, Orozco JJ
1Instituto de Investigación y Control del SIDA, Buenos Aires, Argentina, 2Johnson & Johnson Medical Brazil, 3Universidad de Guadalajara, 4Universidad de Guadalajara, 5Centro de Investigación y Desarrollo, Hospital Infantil Néstor Arancibia, Bogotá, Colombia
OBJECTIVES: To assess, describe and compare the requirements and pathways of medical device coverage in four Latin American countries (LAC) health systems. METHODS: We conducted a literature search (February 2015) on Pubmed, Lilacs and Value in Health Regional Issues journal. We also searched specific websites of Health Technology Assessment (HTA) and regulatory agencies, websites of health and health agencies, and a performed generic Internet search. We included all publications describing aspects related to regulation, coverage, medical technology innovation, and HTA and Economic Evaluation (EE) guidelines. We additionally interviewed key informants from all countries to gather information related to the aforementioned processes. We present here the literature search results. RESULTS: We included 60 studies out of 2190. Five percent of the publications analyzed the four countries jointly, 75% were from Brazil, 8% from Mexico, 5% from Colombia and 7.5% from LAC in general. Half of the studies described the role of the HTA and EE in decision-making and aspects or policies related to innovation (25% and 23.3%). Regarding the description of the coverage process, it was addressed in 11% of the publications focused on technogivalence; and also 10% on regulatory aspects. Remaining publications were methodological guidelines and general descriptions of the health systems and the role of medical devices. All countries had HTA and EE guidelines, although there did not include device specific recommendations. There is a spectrum of HTA formalization for technology incorporation after licensing, higher in Brazil and lower in Argentina CONCLUSIONS: There is scarce information on the processes and requirements to achieve coverage for medical devices in the Latin American countries. Processes differ, and in general not explicit, lack transparency, and usually replicate those of drugs not taking into account the specifcities of medical devices.

MD3

STAPLED HAEMORRHOIDOPEXY TO TREAT HEMORRHOIDS GRADE III AND IV: A SYSTEMATIC REVIEW AND META-ANALYSIS

Luján JM, Pepe C, Riquelme Junior SM, Velasco D, Cabra HA
1Instituto de Investigación y Control del SIDA, Buenos Aires, Argentina, 2Johnson & Johnson Medical Brazil, Sao Paulo, Brazil, 3Johnson & Johnson Medical, Mexico, D.F., Mexico
OBJECTIVES: Hemorrhoids are not life-threatening, but they can cause itching, bleeding and pain, worsening quality of life. Stapled haemorrhoidopexy (SH) is a specially designed circular stapler used to cut out a strip of the tissue above the hemorrhoids in an area of the rectum that doesn’t feel much pain. The operation helps to reduce the size of the rectum and also helps to remove the remaining hemorrhoids by reducing their blood supply and makes them less likely to extend out of the anus. The aim of this study was to review and analyze the evidence of SH. METHODS: We systematically reviewed PubMed, EMBASE, Cochrane Central Register of Controlled Trials, Wiley and OVID, were reviewed. The date limit was set to February 10th of 2015. The studies included were, RCT, the intervention being SH, and the comparison, conventional surgical techniques (CS). The primary outcome was adverse events and the patient satisfaction. The second outcome was to evaluate length of stay, patient and time to return to work, only English language was recovered. Quality was assessed with GRADE meta-analysis. RESULTS: meta-analysis was conducted with R. 5.3 for patient satisfaction and length of hospital stay. A total of 65 records were identified in all databases described, 6 records met the inclusion criteria (n=1503) comparing the SH with CST with a mean follow-up of 15 months. Patient preference was higher in SH compared with CST (OR 1.51[1.03-2.2], p=0.03). Length of Stay was significantly lower in SH group (MD -0.74 [-1.27; -0.21]; p=0.0001, n=1299). Adverse events were similar between strategies. SH offers less post-operative pain and fast return to work activities. CONCLUSIONS: SH is a safe and effective treatment to treat hemorrhoids grade III and IV, improve hospital efficiency and has higher patient acceptability.

MD4

COST EFFECTIVENESS OF DRUG COATED BALLOON VERSUS PERCUTANEOUS TRANSLUMINAL BALLOON ANGIOPLASTY IN THE TREATMENT OF PERIPHERAL ARTERIAL DISEASE IN LOWER LIMBS IN BRAZIL

Pepe C, Palhaim L, Follador W, Palhaim W, Valencia J, Orzoco J
1Grupo Resulta, Sao Paulo, Brazil, 2Sense Company, Sao Paulo, Brazil, 3Medtronic, Sao Paulo, Brazil, 4Medtronic, Miami, FL, USA, 5Medtronic, Medellin, Colombia
OBJECTIVES: To evaluate the cost-effectiveness model for Drug-coated Balloon (DCB) vs. Percutaneous Transluminal Balloon Angioplasty (PTA) in the treatment of Peripheral Arterial Disease in lower limbs from Public Healthcare System (SUS) in Brazil. METHODS: An analytical decision model was considered with Target Lesion Restenosis (TLR) Avoided and total cost at the end of two year period as endpoints. An Excel model was developed. Effectiveness data was taken from a pooled analysis and second recvascularization: procedures probabilities were taken with KOL crite- rion. There was no payer perspective. The model was assumed. Total direct costs for reimbursement were taken from Tabet/Database-2014. Because effective- ness and cost were taken as unique values at the end of the two years, discount rate was no applied. Sensitivity Universe analysis was done for DCB vs. PTA. For the Probabilistic Sensitivity Analysis a Monte Carlo Simulation with 1000 iterations.